New nuclear imaging system to boost medical research – UKRI

There is a growing demand from medical research institutions for high resolution, compact imaging tools to evaluate new nuclear medicine therapies and better study and treat disease progression.

A new medical imaging system has been designed to achieve this, focusing on areas such as cancer and cardiovascular and neurodegenerative diseases.

Strategic partnership

The collaboration integrates the Science and Technology Facilities Council’s (STFC) hyperspectral HEXITEC imaging technology into next-generation imaging platforms that will support drug discovery and treatment development.

MH3D’s systems enable low-dose single photon emission computed tomography (SPECT) and computed tomography imaging while using STFC’s technology to precisely measure gamma rays from radiopharmaceuticals with market-leading accuracy.

This partnership strengthens MH3D’s ability to deliver compact, high-resolution imaging systems built on proven UK technology.

Industry perspectives

Xiaopei Huang, CEO of MH3D, said:

Our core mission at MH3D is to empower researchers with the tools they need to better understand disease mechanisms and therapeutic responses. This partnership with STFC enables us to incorporate world-class technology into our imaging systems, strengthening our position to achieve our goal.

Matt Wilson, Detector Development Group Lead at STFC’s Technology Department, added:

This exciting partnership enables STFC’s UK designed and built HEXITEC detection technology to be incorporated into MH3D’s cutting edge scanners, driving the development of new therapeutics and ultimately bringing patient benefit.

The collaboration marks a significant step toward advancing medical imaging in pre-clinical research, potentially benefiting patients through improved therapeutic development.